KCNJ11 and Alzheimer disease: It is of special interest as an efficient AD therapeutic target because BIR promotes many key features of the disorder, including apoptosis [15, 16], mitochondrial dysfunction [16, 17], oxidative stress [15, 17], metabolic dysfunction [16], vascular dysfunction [18, 19], increased Aβ generation [15–17, 20], decreased Aβ clearance [21, 22], tau phosphorylation [15, 16, 23], synaptic dysfunction [24–26], and cognitive deficits [15, 25, 27].